TrialThe Journal of clinical investigation2014

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Luis J Schwarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.